AR046086A1 - Derivados de 1,3- benzoxazolilo como inhibidores de quinasa - Google Patents
Derivados de 1,3- benzoxazolilo como inhibidores de quinasaInfo
- Publication number
- AR046086A1 AR046086A1 ARP040103452A ARP040103452A AR046086A1 AR 046086 A1 AR046086 A1 AR 046086A1 AR P040103452 A ARP040103452 A AR P040103452A AR P040103452 A ARP040103452 A AR P040103452A AR 046086 A1 AR046086 A1 AR 046086A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- atoms
- mono
- scf3
- unsubstituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229910006074 SO2NH2 Inorganic materials 0.000 abstract 2
- 125000004429 atom Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000000565 sulfonamide group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 102100022014 Angiopoietin-1 receptor Human genes 0.000 abstract 1
- -1 COOA Chemical group 0.000 abstract 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical group O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 abstract 1
- 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
- 108091008605 VEGF receptors Proteins 0.000 abstract 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000000644 propagated effect Effects 0.000 abstract 1
- 102000009929 raf Kinases Human genes 0.000 abstract 1
- 108010077182 raf Kinases Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
El presente se refiere a su composición y uso para el tratamiento de enfermedades, en especial tumores y/o enfermedades que son causadas, mediadas y/o propagadas por angiogénesis. Los compuesos de la fórmula (1) son inhibidores eficaces de las tirosina quinasas, en particular TIE-2 y VEGFR, y de las Raf-quinasas. Reivindicación 1: Compuestos de la fórmula (1), en donde significan: R1, R2, R3 en cada caso, de modo independiente entre sí, R, Hal, CN, NO2, NHR, NRR, NHCOR, NHSO2R, OR, CO-R, CO-NHR, CF3, OCF3, SCF3, SO3R, SO2R, SO2NR, SR, COOH o COOR; R es H o A, AR, Het, (CH2)qHet o (CH2)qAr insustituido o mono, di, tri o tetrasustituido con R4; a es alquilo no ramificado, ramificado o cíclico C1-14, en donde uno o dos grupos CH2 pueden estar reemplazados por átomos de O o S y/o por grupos -CH=CH- y/o también 1-7 átomos de H pueden estar reemplazados por F y/o Cl; Ar es fenilo, naftilo o bifenilo insustituido o mono, di o trisustituido con A, Hal, OH, OA, CN, NO2, NH2, NHA, NA2, NHCOA, SCF3, SO2A, CO-OH,COOA, CONH2, CONHA, CONA2, NHSO2A, SO2NH2, SO2NHA, SO2NA2, CHO o COA; Het es un heterociclo mono o bicíclico saturado, insaturado o aromático con 1 a 4 átomos de N, O y/o S, que puede estar insustituido o mono, di o trisustituido con el oxígeno del carbonilo, Hal, A, -(CH2)b-Ar, -(CH2)b-cicloalquilo, OH, OA, NH2, NHA, NA2, NO2, CN, COOH, COOA, CONH2, CONHA, CONA2, NHCOA, NHCONH2, NHSO2A, CHO, COA, SO2NH2 y/o S(O)gA; Hal es F, Cl, Br o I; R4 es Hal, OH, CN, NO2, CF3, OCF3, SCF3, SO2A, u OA; X es O, S,SO2NH o NH; el circulo Y es fenilo o un heterociclo aromático monocíclico con 1 a 4 átomos de N, O y/o S; b es 0, 1, 2, 3 o 4; g es 0, 1 o 2; n, m, p, q son en cada caso, de modo independiente entre sí, 1, 2, 3 ó 4; así como sus sales, derivados, solvatos y estereoisómeros farmacéuticamente inocuos, incluyendo sus mezclas en todas las proporciones.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10344223A DE10344223A1 (de) | 2003-09-24 | 2003-09-24 | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR046086A1 true AR046086A1 (es) | 2005-11-23 |
Family
ID=34353052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040103452A AR046086A1 (es) | 2003-09-24 | 2004-09-24 | Derivados de 1,3- benzoxazolilo como inhibidores de quinasa |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US8242128B2 (es) |
| EP (1) | EP1664039B1 (es) |
| JP (1) | JP5103013B2 (es) |
| AR (1) | AR046086A1 (es) |
| AU (1) | AU2004281879B2 (es) |
| CA (1) | CA2539767C (es) |
| DE (1) | DE10344223A1 (es) |
| WO (1) | WO2005037829A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2319693C9 (ru) | 1999-01-13 | 2008-08-20 | Байер Копэрейшн | Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты) |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ES2377847T3 (es) | 1999-01-13 | 2012-04-02 | Bayer Healthcare Llc | Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38 |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| ES2288694T3 (es) | 2003-05-20 | 2008-01-16 | Bayer Pharmaceuticals Corporation | Diaril ureas para enfermedades mediadas por el receptor del factor de crecimiento derivado de plaquetas. |
| KR101139557B1 (ko) | 2003-07-23 | 2012-04-30 | 바이엘 파마슈티칼스 코포레이션 | 질환 및 상태의 치료 및 예방을 위한 플루오로 치환오메가-카르복시아릴 디페닐 우레아 |
| US7517995B2 (en) | 2006-04-06 | 2009-04-14 | Boehringer Ingelheim International Gmbh | Thiazolyl-dihydro-cyclopentapyrazole |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| US20070259855A1 (en) * | 2006-04-06 | 2007-11-08 | Udo Maier | Thiazolyl-dihydro-indazole |
| EP1900729A1 (en) | 2006-09-15 | 2008-03-19 | Novartis AG | Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors |
| WO2009111280A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| CN102015707A (zh) * | 2008-02-29 | 2011-04-13 | 阵列生物制药公司 | Raf抑制剂化合物及其使用方法 |
| CN102149712A (zh) * | 2008-02-29 | 2011-08-10 | 阵列生物制药公司 | 吡唑并[3，4-b]吡啶Raf抑制剂 |
| ES2392482T3 (es) * | 2008-02-29 | 2012-12-11 | Array Biopharma, Inc. | Derivados de imidazo[4,5-b] piridina usados como inhibidores de RAF |
| AU2009262199B2 (en) | 2008-06-27 | 2012-08-09 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
| TWI396689B (zh) | 2008-11-14 | 2013-05-21 | Amgen Inc | 作為磷酸二酯酶１０抑制劑之吡衍生物 |
| TW201030001A (en) | 2008-11-14 | 2010-08-16 | Amgen Inc | Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors |
| EP2590957B1 (en) | 2010-07-09 | 2014-11-12 | Pfizer Limited | N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels |
| JP2016535042A (ja) * | 2013-10-30 | 2016-11-10 | ノバルティス アーゲー | ２−ベンジル−ベンゾイミダゾール補体因子ｂ阻害剤およびその使用 |
| CN111372579B (zh) | 2017-10-30 | 2023-08-22 | 神经孔疗法股份有限公司 | 取代的苯基磺酰基苯基三唑硫酮和其用途 |
| KR102838917B1 (ko) * | 2022-09-27 | 2025-07-28 | 이화여자대학교 산학협력단 | 4-아미노-부탄아미드를 포함하는 신규한 벤조옥사졸 유도체 및 이의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6579857B1 (en) * | 1999-06-11 | 2003-06-17 | Evanston Northwestern Healthcare Research Institute | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors |
| US7041691B1 (en) * | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| JP4295458B2 (ja) * | 1999-06-30 | 2009-07-15 | アムジェン インコーポレイテッド | Ｐｐａｒ−ガンマ活性調節用化合物 |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| CA2427750C (en) * | 2000-11-04 | 2011-01-04 | Aventis Pharma Limited | Substituted alkanoic acids |
| JP2004517080A (ja) | 2000-11-29 | 2004-06-10 | グラクソ グループ リミテッド | Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体 |
| GB0102687D0 (en) * | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| US20030009034A1 (en) * | 2001-03-22 | 2003-01-09 | Neil Wishart | Transition metal mediated process |
| MXPA03008560A (es) * | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| EP1463730B1 (en) * | 2001-12-17 | 2006-04-19 | SmithKline Beecham Corporation | Pyrazolopyridazine derivatives |
| US7071216B2 (en) * | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
| US20030225131A1 (en) * | 2002-04-05 | 2003-12-04 | Burgey Christopher S. | Thrombin inhibitors |
| DE10349587A1 (de) * | 2003-10-24 | 2005-05-25 | Merck Patent Gmbh | Benzimidazolylderivate |
-
2003
- 2003-09-24 DE DE10344223A patent/DE10344223A1/de not_active Withdrawn
-
2004
- 2004-09-01 JP JP2006527292A patent/JP5103013B2/ja not_active Expired - Fee Related
- 2004-09-01 CA CA2539767A patent/CA2539767C/en not_active Expired - Fee Related
- 2004-09-01 WO PCT/EP2004/009743 patent/WO2005037829A1/de not_active Ceased
- 2004-09-01 AU AU2004281879A patent/AU2004281879B2/en not_active Ceased
- 2004-09-01 EP EP04764704.5A patent/EP1664039B1/de not_active Expired - Lifetime
- 2004-09-01 US US10/573,176 patent/US8242128B2/en not_active Expired - Fee Related
- 2004-09-24 AR ARP040103452A patent/AR046086A1/es unknown
-
2012
- 2012-05-08 US US13/466,464 patent/US20120220611A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2539767C (en) | 2013-02-05 |
| JP2007506687A (ja) | 2007-03-22 |
| EP1664039B1 (de) | 2014-03-05 |
| AU2004281879B2 (en) | 2011-04-07 |
| CA2539767A1 (en) | 2005-04-28 |
| WO2005037829A1 (de) | 2005-04-28 |
| EP1664039A1 (de) | 2006-06-07 |
| US20120220611A1 (en) | 2012-08-30 |
| AU2004281879A1 (en) | 2005-04-28 |
| JP5103013B2 (ja) | 2012-12-19 |
| US8242128B2 (en) | 2012-08-14 |
| US20060281762A1 (en) | 2006-12-14 |
| DE10344223A1 (de) | 2005-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR046086A1 (es) | Derivados de 1,3- benzoxazolilo como inhibidores de quinasa | |
| AR067506A1 (es) | Derivados de quinazolinamida | |
| AR045626A1 (es) | Derivados del bencil- bencimidazolilo | |
| AR046140A1 (es) | Derivados de bencimidazolilo, procedimiento de preparacion y usos | |
| AR046748A1 (es) | Derivados de amina que inhiben,regulan,y/o modulan tirosinaquinasas,composiciones farmaceuticas que los contienen,procedimientos de preparacion y compuestos intermediarios | |
| AR082726A1 (es) | Derivados de triazolopirazina | |
| AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
| AR082722A1 (es) | Derivados de pirimidina | |
| AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
| AR080803A1 (es) | Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias. | |
| AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
| PE20060570A1 (es) | Compuestos de quinazolina e isoquinolina piperidilo sustituidos como inhibidores de fosfodiesterasa pde-10 | |
| PE20021010A1 (es) | Derivados espirociclicos como inhibidores de fosfodiesterasa-7 | |
| DOP2002000482A (es) | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares | |
| AR055772A1 (es) | Aza -heterociclos como inhibidores de quinasas, preparacion de los compuestos y medicamento preparado en base al compuesto | |
| AR082728A1 (es) | Imidazolonilquinolinas utiles para tratar el cancer, composiciones farmaceuticas que las contienen, proceso de sintesis, intermediarios de dicha sintesis y procedimiento para prepararlos | |
| GT200600398A (es) | Compuestos de isoindol-imida y composiciones que los incluye y metodos para su uso | |
| UY27234A1 (es) | Inhibidores novedosos de tirosina cinasa | |
| AR085471A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
| AR079541A1 (es) | Compuestos sustituidos de n-(1h-indazol-4-il) imidazo (1,2-a) piridin-3-carboxamida como inhibidores de cfms | |
| AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
| AR074493A1 (es) | Derivados de quinazolinamida | |
| AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
| AR028914A1 (es) | 2-guanidino-4-aril-quinazolinas como inhibidores de nhe-3 | |
| AR045733A1 (es) | Derivados de aminobencimidazol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |